Resources Repository
-
ReportPublication 2013Decision and Simulation Modeling Alongside Systematic Reviews
This chapter is part of a report entitled, Decision and Simulation Modeling in Systematic Reviews, that seeks …
This chapter is part of a report entitled, Decision and Simulation Modeling in Systematic Reviews, that seeks to provide guidance for determining when incorporating a decision-analytic model alongside a systemic review would be of added value for decision making purposes. The chapter discusses the role of decision analysis and decision-analytic models in health care, specifically within the context of the current emphasis on evidence-based medicine and the proliferation of systematic reviews. It describes the types of model available…
Dynamic Simulation | Microsimulation | Dynamic Transmission | State-Transition | Evidence Synthesis | Health Systems | Clinical Care | Health/Medicine -
ReportPublication 2016Modeling to Inform Strategies to Improve Population Health
This workshop report summarizes a workshop convened by the Institute of Medicine to explore the potential …
This workshop report summarizes a workshop convened by the Institute of Medicine to explore the potential uses of simulation and other types of modeling for improving health. Participants worked to identify how modeling could inform population health decision making (selecting and refining potential strategies, ranging from interventions to investments) based on lessons learned from models that have been, or have not been, used successfully, opportunities and barriers to incorporating models into decision making, and data needs and…
Dynamic Simulation | Microsimulation | Mathematical Models | State-Transition | Decision Analysis | Chronic Disease/Risk | Environmental Health | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Government/Law | Health/Medicine | North America -
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Preferences/Values | Mathematical Models | Technology Assessment | Priority Setting/Ethics | Costing Methods | Health Outcomes | Value of Information | Cost-Effectiveness Analysis | Operations Research | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Economics/Finance | Health/Medicine | Science/Technology | Global -
ReportPublication 2015Modeling to Improve Policy Decisions in the Americas: Noncommunicable Diseases
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only …
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only to human health, but also to a country’s economic development and growth. The evidence on both of these counts is compelling. In 2012, cardiovascular disease, diabetes, cancers, chronic respiratory conditions including asthma, and other NCDs were the cause of 4.5 million deaths in the Americas. Of that total number, 1.5 million of them were premature, occurring among people aged 30-69…
Microsimulation | Mathematical Models | State-Transition | Priority Setting/Ethics | Costing Methods | Decision Analysis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Mental Health | Health/Medicine | Latin America & Caribbean -
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Preferences/Values | Technology Assessment | Priority Setting/Ethics | Evidence Synthesis | Value of Information | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Mental Health | Health Systems | Business/Industry | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | North America | Europe -
OrganizationWeb Portal 2024One Health Trust
One Health Trust, formally the Center for Disease Dynamics, Economics & Policy (CDDEP), was founded …
One Health Trust, formally the Center for Disease Dynamics, Economics & Policy (CDDEP), was founded with the objective of using research to support better decision-making in health policy. One Health Trust researchers employ a range of expertise—including economics, epidemiology, disease modeling, risk analysis, and statistics—to conduct actionable, policy-oriented research on malaria, antibiotic resistance, disease control priorities, environmental health, alcohol and tobacco, and other global health priorities. One Health Trust projects are global in scope, spanning…
Mathematical Models | Technology Assessment | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Social Determinants | Environmental Health | Policy/Regulation | Climate/Environment | Economics/Finance | Health/Medicine | Global | Sub-Saharan Africa | Asia & Pacific -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Preferences/Values | Technology Assessment | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Mental Health | Health Systems | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine | Science/Technology | North America -
ReportPublication 2003ISPOR Task Force Report: Good Practice for Decision Analytic Modeling in Health-Care
This report describes the consensus of a task force convened to provide modelers with guidelines …
This report describes the consensus of a task force convened to provide modelers with guidelines for conducting and reporting modeling studies. While published more than a decade ago, it remains a clearly written resource for thinking about how to accurately describe the components of models and their quality. Criteria for assessing the quality of models fell into three areas: model structure, data used as inputs to models, and model validation. Several major themes cut across…
Mathematical Models | Calibration/Validation | Health/Medicine | Science/Technology | Global -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Preferences/Values | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation | Government/Law | North America